Government Law & Strategies

"Persistence and determination alone are omnipotent.” - Calvin Coolidge

Henry Menn has over 25 years of experience in health care legislative and administrative advocacy before federal and state governments. He has represented numerous health care trade associations and companies on Medicare payment and FDA policies as well as general business matters, with a particular focus on federal tax and trade issues. His broad range of health clients are from the pharmaceutical, medical device, health insurance and pharmacy sectors, in addition to ambulatory surgery center (ASC), skilled nursing facility (SNF), hospital and kidney dialysis providers.

Henry also has extensive government service experience having served in the United States Senate as the Chief of Staff to Senator Bob Graham and on the Veterans Affairs Committee as Minority Staff Director and Chief Counsel. After serving on the 1993 Presidential Transition team, President Clinton appointed Henry as Special Assistant for Legislative Affairs at the Food & Drug Administration.

Before joining Brown Rudnick, Henry opened the Washington office for Boehringer Ingelheim Pharmaceuticals, Inc. and was responsible for developing government relations strategies, managing the state lobbying team, and advancing the company policy positions before the Congress, federal agencies and trade associations. In addition to his in-house corporate experience, Henry has worked for three health care trade associations handling policy development, coalition building and government relations lobbying.

Henry is politically active and currently serves on the steering committee for the Moderate Democrat PAC. His previous political work involves the 1986 Bob Graham U.S. Senate and the 1992 Clinton/Gore presidential campaigns.


The Physician Payment Sunshine Act (Public Law 111-148 and CMS Proposed Rule 5060-P).

Medicaid average manufacturer price (AMP) methodology for generic drug reimbursement (Public Law 109-171, DRA 2005; Public Law 110-275, MIPPA 2008; Public Law 111-148, PPACA 2010).

Regulatory pathway for FDA approval of follow-on biologic products (Public Law 111-148, PPACA 2010).

Temporary duty suspension by Congress of an intermediate in the production of a drug that treats HIV (Public Law 111-227).

Federal tax policy relating to deferral, R&D tax credit, medical device excise tax, repeal of the LIFO inventory account method and Senate ratification of the US-German Income Tax Protocol (Treaty Doc. 109-20).

Department of Veteran Affairs pain management policy (Public Law 110-387).

The Ryan White CARE Act Reauthorization (PL 109-415) and federal funding of AIDS Drug Assistance Programs.

Federal legislation relating to the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417, “Hatch-Waxman Act”).

The Prescription Drug User Fee Act (PDUFA) Reauthorizations of 1997 (Public Law 110-85), 2007 (Public Law) and 2012.

Federal public health legislation involving prescription drug shortages, healthcare-associated infections (HAIs), drug importation, antimicrobial resistance and drug pedigree.

Medicare DMEPOS Competitive Bidding relating to blood glucose testing strips (CMS Proposed Rule 1503-P).

Pharmaceutical pricing relating to Medicare Part B Average Sales Price (ASP) payment methodology (CMS Final Rule 1321-FC), 340(B) Program and Medicare Part D price negotiations by the Federal Government (Public Law 108-173, MMA 2003).

Small group health insurance reform (Employee Health Care Access Act, Chapter 93-129, Laws of Florida).


University of Miami School of Law – J.D., 1990
Purdue University – B.A., 1984

Bar Admissions

District of Columbia
Professional Affiliations
Board of Trustees, Florida House, D.C.
Former Member, Board of Governors, Ford's Theatre
Vice-President and Member, Board of Directors, Brown Rudnick Charitable Foundation
Board of Directors, Catholic Medical Mission Board